主笔:于梅君 爱丁堡大学的科学家想:"能不能让塑料'死得其所',变成更有价值的东西?"他们通过一种被称为"洛森重 排"的化学反应,成功将废弃塑料瓶转化为常用的镇痛药——对乙酰氨基酚(即扑热息痛),转化率高达 92%。 你喝完水,随手把空塑料瓶扔进垃圾桶——它可能就此开启一场"逆袭之旅":48小时后,它或许会变成你感 冒时吃的止痛药。废弃塑料瓶变救命药,这个奇幻魔术是怎么实现的? 从"污染魔头"到"资源宝贝" 全球每年生产4.14亿吨塑料,其中42%用来做包装——比如你手里的矿泉水瓶、外卖餐盒、快递袋。这些 塑料制品的"寿命"短得可怜:平均使用12分钟,却要在地球上存在450年。 对含氯塑料进行回收升级,可获得高附加值和多功能性产品 这些塑料可能先被送到垃圾中转站,然后被运到填埋场,和腐烂的食物、废旧电池做"邻居",慢慢渗出有毒 物质污染土壤；或者被送到焚烧厂,在1000℃高温下变成灰烬,同时释放出致癌的二噁英,飘散到空气中； 就算被回收,也大多降级成低价值产品,比如做成地毯纤维或塑料长椅——这些产品用几年后,还是会变成 垃圾,继续它的"污染之旅"。 因为要让它发生反应,需要使用强酸、强碱或高温等"暴力手段", ...

Core Insights - The research team led by Zhang Xiaoheng from the University of Chinese Academy of Sciences has developed a new method for modifying aromatic amines, which could significantly impact the pharmaceutical industry by reducing costs and improving safety in drug synthesis [1][2][3] Group 1: Research Breakthrough - The team introduced a "direct deamination" strategy that replaces stable carbon-nitrogen bonds in aromatic amines with various functional chemical bonds, avoiding the use of hazardous diazonium intermediates [1][3] - This new method is expected to address the cost challenges associated with anticancer drugs and has received high praise from industry experts, including Pfizer's senior R&D director [1][2] Group 2: Traditional Method Limitations - The traditional method for removing amino groups from aromatic amines involves converting them into unstable diazonium salts, which pose explosion risks and generate significant waste [2][4] - The existing process is not aligned with current green chemistry goals, as it consumes large amounts of copper and incurs high pollution treatment costs [2][4] Group 3: Innovative Approach - The research involved extensive experimentation, leading to the discovery that N-nitrosoamines, initially considered a minor byproduct, play a crucial role in facilitating the synthesis of target products [4][5] - The new method allows for the direct cleavage of carbon-nitrogen bonds under mild conditions, using inexpensive reagents, and eliminates the need for hazardous intermediates [5][6] Group 4: Industrial Application Potential - The new strategy has been tested on various nitrogen-containing intermediates commonly used in pharmaceuticals, demonstrating its applicability across a wide range of drug precursors [6] - Collaborations with pharmaceutical companies are underway to implement this technology in the synthesis of drug intermediates, potentially reducing production costs by 40%-50% [6]

Core Insights - The participation of Sichuan's biopharmaceutical companies in the 2025 World Pharmaceutical Raw Materials Europe Exhibition marks a significant step towards integrating into the global industrial chain [1][3] - Sichuan's exhibition area exceeds 900 square meters, ranking among the top in China's exhibition groups [2] - The delegation consists of 73 local pharmaceutical and related enterprises, with over 150 participants showcasing key products such as specialty raw materials, high-end medical devices, and innovative biopharmaceuticals [1][2] Industry Overview - The World Pharmaceutical Raw Materials Europe Exhibition is the largest and most influential event in the pharmaceutical industry, attracting over 2,500 exhibitors from more than 140 countries and regions [1][2] - The exhibition focuses on green pharmaceuticals and biomanufacturing, aligning well with the development direction of Sichuan's biopharmaceutical industry [2][3] Company Highlights - Notable companies participating include Sichuan Kelun Pharmaceutical, Chengdu Kanghua Biological Products, and Chengdu Beite Pharmaceutical, covering the entire biopharmaceutical industry chain in Sichuan [3] - Sichuan Xinmeijia Biopharmaceutical Co., Ltd. is the largest fish oil producer in China, with significant orders expected during the exhibition, including a projected 30 million yuan in contracts [4] - Chengdu Okang Pharmaceutical Co., Ltd., listed on the Beijing Stock Exchange, is expanding from health food and food additives into the raw materials market [4] Strategic Goals - The event is part of the "Chuanxing Tianxia" international market expansion initiative, aiming to showcase Sichuan's innovative strength and development vitality in the biopharmaceutical sector [1][3] - The strategy emphasizes building networks and strengthening supply chains to enhance international order acquisition and promote high-quality industry development [4]

Core Viewpoint - The article highlights the strategic transformation of Wuchan Zhongda Health, focusing on innovation-driven and green transformation in the pharmaceutical and healthcare sector, aiming to integrate medical services with pharmaceutical manufacturing and investment funds [1][5]. Group 1: Company Transformation - Wuchan Zhongda Health is shifting from a primary focus on medical services to a dual approach that includes pharmaceutical manufacturing and investment funds, emphasizing innovation and green transformation [1]. - Hongyuan Pharmaceutical, a subsidiary, has evolved from a traditional chemical factory to a modern green pharmaceutical enterprise, adopting enzyme-catalyzed processes and eliminating traditional chemical synthesis methods [3][4]. Group 2: Environmental Commitment - The company prioritizes ecological responsibility, integrating pollution reduction and safety into its research and development processes, particularly in the production of atorvastatin intermediates [4]. - Hongyuan Pharmaceutical has achieved significant reductions in resource consumption, with steam usage down by 30%, electricity by 17%, and solvents by 40% [4]. Group 3: Investment and Innovation - Wuchan Zhongda Health is integrating innovation platforms with investment funds to break down barriers between research and application, focusing on the pharmaceutical health industry [5][7]. - The company is developing China's first comprehensive solution for Boron Neutron Capture Therapy (BNCT), which has shown promising results in cancer treatment, with a complete response rate of 46% in Japanese patients [5][6]. Group 4: Future Prospects - The pharmaceutical industry fund is seen as a microcosm of Wuchan Zhongda Health's development of new productive forces, accelerating the layout of innovative drugs and medical devices [7]. - The company aims to enhance its independent research capabilities and integrate technological and industrial innovation to contribute to the economic and social development of Zhejiang Province [7].

Group 1 - The core idea of the article is the innovative transformation of plastic waste into a valuable pain relief medication, acetaminophen, using engineered E. coli bacteria [1][3][4] - The research highlights a novel method of utilizing waste plastic, specifically PET plastic from bottles, as raw material for drug production through metabolic engineering and organic chemistry [3][4] - The process involves breaking down PET into basic molecules, which are then converted into drug precursors within the bacteria, achieving a high yield of 92% for acetaminophen [3][4] Group 2 - This research marks the first successful instance of producing pharmacologically valuable small molecules from discarded plastics within microbial systems, paving the way for advancements in resource recycling and green pharmaceuticals [4] - Future plans include exploring the potential of other types of plastics for similar transformations and identifying additional bacteria capable of such processes, as well as the possibility of producing a wider variety of drugs [4][5] - The vision is to establish "bio-factories" that utilize microorganisms to convert plastic waste into energy, pharmaceuticals, and even food, transforming discarded plastic bottles into valuable raw material "seeds" [5]